[{"NetIncomeLoss_2_Q2_USD":-22290000.0,"PaidInKindInterest_2_Q2_USD":0.0,"AccruedLiabilitiesCurrent_0_Q2_USD":9114000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":2093000.0,"InterestPaidNet_2_Q2_USD":2403000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":841000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":150000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":10700000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-25000.0,"Depreciation_2_Q2_USD":142000.0,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":108403000.0,"IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_2_Q2_USD":5943000.0,"FinanceLeaseInterestPaymentOnLiability_2_Q2_USD":10000.0,"FinanceLeaseInterestPaymentOnLiability_1_Q2_USD":4000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":830000.0,"AssetsCurrent_0_Q2_USD":151826000.0,"OperatingLeaseExpense_2_Q2_USD":427000.0,"OperatingLeaseExpense_1_Q2_USD":213000.0,"CommonStockSharesIssued_0_Q2_shares":28754192.0,"FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":65000.0,"FinanceLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":10000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":815000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_2_Q2_USD":-140000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":-12000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"FinanceLeaseInterestExpense_1_Q2_USD":4000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":10000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":2450203.0,"SellingAndMarketingExpense_1_Q2_USD":6659000.0,"SellingAndMarketingExpense_2_Q2_USD":12318000.0,"FinanceLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":0.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":35000.0,"FinanceLeaseInterestExpense_2_Q2_USD":10000.0,"AccountsAndOtherReceivablesNetCurrent_0_Q2_USD":15111000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":28744000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":26750000.0,"CommonStockValue_0_Q2_USD":29000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":280000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":281000.0,"GainsLossesOnExtinguishmentOfDebt_1_Q2_USD":2065000.0,"GainsLossesOnExtinguishmentOfDebt_2_Q2_USD":2065000.0,"FinanceLeasePrincipalPayments_1_Q2_USD":29000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":108388000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":58000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":44343000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":3288000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":5605000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":11084000.0,"ClassOfWarrantOrRightOutstanding_0_Q2_shares":48683.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":448000.0,"ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_0_Q2_USD":3003000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":153000.0,"FinanceLeaseLiabilityPaymentsDue_0_Q2_USD":140000.0,"IncreaseDecreaseInInventories_2_Q2_USD":43000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":5184000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":10299000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"OperatingLeaseLiability_0_Q2_USD":2626000.0,"FinanceLeaseLiability_0_Q2_USD":130000.0,"Liabilities_0_Q2_USD":71958000.0,"DeferredRevenueNoncurrent_0_Q2_USD":15132000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":638965000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":127630000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":615000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":1230000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-10010000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-22290000.0,"FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":75000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":2013000.0,"Assets_0_Q2_USD":178823000.0,"ShareBasedCompensation_2_Q2_USD":2168000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":2353000.0,"InterestExpense_1_Q2_USD":1376000.0,"InterestExpense_2_Q2_USD":2722000.0,"NonoperatingIncomeExpense_1_Q2_USD":969000.0,"NonoperatingIncomeExpense_2_Q2_USD":-376000.0,"AccountsPayableCurrent_0_Q2_USD":5421000.0,"DeferredRevenueCurrent_0_Q2_USD":1008000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":127780000.0,"LiabilitiesCurrent_0_Q2_USD":16250000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":3135000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-25642000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":1180000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":2168000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":140000.0,"FinanceLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.125,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":849000.0,"CommonStockSharesOutstanding_0_Q2_shares":28754192.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":3704000.0,"LongTermDebtNoncurrent_0_Q2_USD":36235000.0,"NetIncomeLoss_1_Q2_USD":-10010000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":515000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"OperatingLeasePayments_1_Q2_USD":221000.0,"OperatingLeasePayments_2_Q2_USD":442000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":23979000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":183000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2_Q2_USD":173000.0,"FinanceLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":0.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.125,"FinanceLeaseRightOfUseAssetAmortization_1_Q2_USD":30000.0,"FinanceLeaseRightOfUseAssetAmortization_2_Q2_USD":62000.0,"FinanceLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":0.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":2198000.0,"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0_Q2_USD":12.33,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-421000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":82721000.0,"VariableLeaseCost_1_Q2_USD":9000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":178823000.0,"PreferredStockValue_0_Q2_USD":null,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":68322000.0,"InventoryNet_0_Q2_USD":5381000.0,"OperatingIncomeLoss_1_Q2_USD":-10979000.0,"OperatingIncomeLoss_2_Q2_USD":-21914000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":3457000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":9013000.0,"CommonStockSharesAuthorized_0_Q2_shares":300000000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":346000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":662000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":108403000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":16336000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-532970000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":1180000.0,"VariableLeaseCost_2_Q2_USD":18000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":25000.0,"StockholdersEquity_0_Q2_USD":106865000.0,"OtherLiabilitiesCurrent_0_Q2_USD":707000.0,"FinanceLeaseLiabilityCurrent_0_Q2_USD":95000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":2328000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":2168000.0,"ProfitLoss_2_Q2_USD":-22290000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.83,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":1354000.0,"OperatingExpenses_1_Q2_USD":19992000.0,"OperatingExpenses_2_Q2_USD":38250000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":613000.0,"FinanceLeaseRightOfUseAsset_0_Q2_USD":124000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.35,"AccruedProfessionalFeesCurrent_0_Q2_USD":616000.0,"Ticker":"EYPT","CIK":"1314102","name":"EYEPOINT PHARMACEUTICALS, INC.","OfficialName":"EyePoint Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"408871503.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210806"}]